Chemomab Therapeutics (STU:2QV0) Beginning Cash Position : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Beginning Cash Position?

Chemomab Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €0.00 Mil.

Chemomab Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€14.39 Mil) to Dec. 2023 (€12.47 Mil) and declined from Dec. 2023 (€12.47 Mil) to Dec. 2024 (€8.95 Mil).

Chemomab Therapeutics Beginning Cash Position Historical Data

The historical data trend for Chemomab Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Beginning Cash Position Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

10.10

10.38

14.39

12.47

8.95

Chemomab Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															-	-	-	-	-

Chemomab Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Chemomab Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

CMMB:USA 2QV0:Germany

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines